In Taiwan, biologics are registered through the Taiwan FDA (TFDA) with a process similar to that for chemical drugs but requiring more detailed clinical, manufacturing, and quality data. Submissions must include evidence of Good Manufacturing Practices (GMP) compliance, stability studies, and immunogenicity assessments. Biologics may also benefit from accelerated review pathways for priority products.